News from Zyme and the companies we work with.

April 21, 18

Cobra Biologics Receives the Queen’s Award for Enterprise in International Trade

The UK’s most prestigious business award granted in recognition of outstanding achievement in the export of services for gene and immunotherapy products. 21 April 2018, Keele, UK: Cobra Biologics (“Cobra”) a leading international contract development and manufacturing organisation (“CDMO”), today … Continue reading →

April 21, 18

British Breast Cancer Company, Endomag, Wins Queen’s Award

UK company providing more accurate tools for breast cancer removal receives prestigious business award Cambridge, UK, 21 April 2018: Endomag, the surgical guidance company, today announced it has received the Queen’s Award for Enterprise in Innovation for 2018. The Award … Continue reading →

April 18, 18

Fusion Pharmaceuticals Licenses Isogenica’s CIS Display Technology

Technology will be used to progress Fusion’s pipeline of alpha therapeutics for the treatment of cancers Cambridge, UK and Hamilton, Canada, 18th April 2018: Isogenica Ltd and Fusion Pharmaceuticals Inc (Fusion) today announced a new licensing agreement that will leverage … Continue reading →

April 17, 18

PATH and Mologic advance a new diagnostic test to support malaria elimination

Test will expand the range of diagnostic options available to guide treatment of Plasmodium vivax Bedfordshire, UK and Seattle, Washington, USA, April 17, 2018: PATH and United Kingdom-based test developer Mologic have entered an agreement to advance a new rapid … Continue reading →

April 16, 18

PhoreMost and Plexxikon collaborate to identify novel drug targets

Cambridge, UK, 16 April 2018: PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo. Under the agreement, PhoreMost … Continue reading →

April 13, 18

Sphere Fluidics selected as a finalist for 2018 Red Herring Top 100 Europe Award

Cyto-Mine Single Cell Analysis System recognized among top innovative and disruptive products in Europe Cambridge, UK, 13 April 2018: Sphere Fluidics, a company providing single cell analysis systems underpinned by its patented picodroplet technology, announced today it has been selected … Continue reading →

April 12, 18

Horizon enters into partnership with Pirbright Institute to support research into improvement of vaccine yields

• Extends Horizon’s biomanufacturing capabilities into vaccine manufacture • Research supported by a grant from the Canadian International Development Research Centre, funded by the Bill and Melinda Gates foundation Cambridge, UK, 12 April, 2018: Horizon Discovery Group plc (LSE: HZD) … Continue reading →

April 12, 18

Enterprise Therapeutics raises £29 million ($41 million USD) funding

• Series B round co-led by Versant Ventures and Novartis Venture Fund, with Forbion, Epidarex Capital and IP Group completing the syndicate • Funding will advance pipeline of novel treatments for respiratory diseases into clinical development, including Phase 2 proof … Continue reading →

April 9, 18

Owlstone Medical provides Breath Biopsy Services to AstraZeneca to study disease drivers in Asthma and COPD

Collaboration will explore use of Breath Biopsy to identify novel biomarkers to enable personalized medicine applications Cambridge, UK, April 9, 2018: Owlstone Medical, a diagnostics company developing a breathalyzer for disease, today announced it has signed a service agreement with … Continue reading →

April 4, 18

IONTAS and IGEM Therapeutics collaborate to identify novel IgE antibodies for cancer targets

Cambridge, UK, 04 April 2018: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, announced today that it will collaborate with IGEM Therapeutics (IGEM), an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat … Continue reading →